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In a previous issue of Critical Care, Lehmann and 
colleagues analyzed the potential impact of a commer-
cially available PCR-based diagnostic method to test the 
whole blood of septic patients for bacterial DNAemia [1]. 
Th  e evidence they collected is derived from their 
previous prospective observational trial showing reduc-
tion of inadequate treatment days [2] coupled with two 
other unrelated studies on outcomes [3,4]. Th  e authors 
then developed a mathematical model to suggest that 
PCR-based detection of pathogens early during sepsis 
might reveal cost-eﬀ  ective, under-deﬁ  ned conditions. Th  is 
is clearly a landmark paper in molecular microbial diag-
nostics but its predictions derive from numerous assump-
tions and therefore warrant a careful interpre  tation.
It is now obvious that adequate empiric therapy must 
be administered as soon as possible to septic patients in 
order to reduce mortality [5]. An early switch, however, 
from an empiric regimen initiated on clinical clues to an 
adapted therapy based on a probabilistic antimicrobial 
susceptibility, itself derived from the organism identiﬁ  -
cation, might lead to more targeted and more appropriate 
therapy. Th   is implies broadening the antimicrobial 
spectrum for an unexpected organism and/or narrowing 
the empiric coverage (for example, by stopping glyco-
peptides if an Escherichia coli strain is detected). Beneﬁ  ts 
might therefore derive from an improved clinical 
outcome and/or from savings due to drug adjustments. 
Th  is strategy could also, however, lead to higher costs 
due to molecular diagnostics and adjusted therapy. And 
here comes the challenge to design such a health-
economic study: one needs to bridge several medical 
disciplines (intensive medicine, laboratory medicine, 
epidemiology and infectious disease special  ists, and so 
forth) to provide the full cost picture. Th  is picture is 
needed to convince our hospital directors to implement 
costly but beneﬁ  cial approaches, by showing them strong 
data supporting a paradigm shift in clinical microbiology.
Lehmann and colleagues have partially overcome these 
hurdles by compiling data from diﬀ   erent studies [1]. 
Importantly, their approach makes several major assump-
tions: molecular testing does not provide false positive 
results (negative results are not considered here – hence, 
the issue of suboptimal detection sensitivity and the 
limited microbial diversity detection of the assay are not 
relevant here); the assay is performed only once, as soon 
as possible; results are rapidly delivered 24 hours per day 
to the physician in charge, who will immediately and 
optimally adjust therapy; the prevalence of positive blood 
cultures should be high (here more than 15%, as observed 
in the emergency room wards and hence mostly detecting 
community-acquired infections); and, ﬁ  nally,  there 
should be a high proportion of inadequate empirical 
treat  ments (here more than 25%, which might be true 
mostly for hospital-acquired infections and therefore in 
wards other than the emergency room). Th  e  applicability 
of this approach is thus highly contextual as a function of 
the local epidemiology, of the respect of antimicrobial 
prescription guidelines, and assuming ideal 24 hours per 
day laboratory support. Th  e  cost-eﬃ   ciency model should 
therefore be assessed by each potential user, for its 
intended target patient population and wards, by using 
its own numbers.
Finally, the compilation of data contains the risk that 
false positive PCR results (for example, the unexpected 
detection of DNA from Pseudomonas aeruginosa or 
yeasts/fungi) might overestimate the rate of inadequate 
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Molecular biology has not yet fully reached 
its ambitious goals in clinical bacteriology. 
Notwithstanding the tremendous technical challenges, 
the detection of nucleic acids directly from the 
blood of septic patients has not been shown cost-
eff  ective or even clinically relevant. Yet the potential 
for rapid molecular detection of circulating DNA 
(DNAemia) coupled to an educated antimicrobial 
drug adaptation has been repetitively advocated as a 
predicted breakthrough. Why do we still remain in such 
uncertainty?
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clinically-irrelevant, expensive and perhaps dangerous 
medical decisions. Th  ese limitations will have to be 
addressed in carefully designed studies.
In the future, such studies will have to conﬁ  rm that the 
rapid availability of such PCR assays – a true logistical 
challenge to most diagnostic laboratories – can indeed be 
followed by changes in therapy and could prove cost-
eﬀ  ective, across diﬀ  erent wards, hospitals and countries. 
Once validated, such molecular assays will probably be 
bundled with computer-assisted antimicrobial prescrip-
tion and electronic reporting tools.
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